Pemphigus vulgaris (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Pemphigus vulgaris" in English language version.

refsWebsite

Global rank English rank

17nih.gov

4^th place

12doi.org

2^nd place

3semanticscholar.org

11^th place

8^th place

1uptodate.com

3,771^st place

2,605^th place

1worldcat.org

5^th place

1web.archive.org

1^st place

1consultantlive.com

low place

1gene.com

low place

1pemphigus.org

low place

1patient.info

low place

7,180^th place

1timesofisrael.com

571^st place

403^rd place

1rarediseases.org

5,181^st place

3,260^th place

1bbc.co.uk

8^th place

10^th place

1harvard.edu

18^th place

17^th place

bbc.co.uk

Gallagher J (2016-07-01). "'Civil war' in immune system can fight disease". BBC News, Health. Retrieved 2016-07-01.

consultantlive.com

Kaplan DL (2009). "Dermclinic". Consultant. 49 (3). Archived from the original on 2012-02-13. Retrieved 2009-04-02.

doi.org

Cholera M, Chainani-Wu N (June 2016). "Management of Pemphigus Vulgaris". Advances in Therapy. 33 (6): 910–958. doi:10.1007/s12325-016-0343-4. PMC 4920839. PMID 27287854.
Beigi PK (2018). "History of Pemphigus Vulgaris". A Clinician's Guide to Pemphigus Vulgaris. Springer, Cham. p. 13. doi:10.1007/978-3-319-67759-0_3. ISBN 978-3-319-67758-3. S2CID 91065046.
King DF, Holubar K (October 1983). "History of pemphigus". Clinics in Dermatology. 1 (2): 6–12. doi:10.1016/0738-081X(83)90019-6. PMID 6400552.
Gupta VK, Kelbel TE, Nguyen D, Melonakos KC, Murrell DF, Xie Y, et al. (July 2011). "A globally available internet-based patient survey of pemphigus vulgaris: epidemiology and disease characteristics". Dermatologic Clinics. 29 (3): 393–404, vii–iii. doi:10.1016/j.det.2011.03.016. PMID 21605804.
Maity, Subhadeep; Banerjee, Ishita; Sinha, Rupam; Jha, Harshvardhan; Ghosh, Pritha; Mustafi, Subhasish (2020). "Nikolsky's sign: A pathognomic boon". Journal of Family Medicine and Primary Care. 9 (2): 526–530. doi:10.4103/jfmpc.jfmpc_889_19. ISSN 2249-4863. PMC 7114071. PMID 32318376.
Ahmed AR, Kaveri S, Spigelman Z (December 2015). "Long-Term Remissions in Recalcitrant Pemphigus Vulgaris". The New England Journal of Medicine. 373 (27): 2693–2694. doi:10.1056/NEJMc1508234. PMID 26716930.
de-la-Rosa-Fernández E, Loizate-Sarrionandia I, González-Rodríguez J, Herrero-Moyano M, Fernández-de-Misa-Cabrera R, Suárez-Hernández J (April 2023). "Ocrelizumab, an alternative to rituximab in refractory pemphigus vulgaris management". Journal of the European Academy of Dermatology and Venereology. 37 (9): e1104 – e1106. doi:10.1111/jdv.19133. PMID 37102356. S2CID 258355167.
Ellebrecht CT, Choi EJ, Allman DM, Tsai DE, Wegener WA, Goldenberg DM, Payne AS (December 2014). "Subcutaneous veltuzumab, a humanized anti-CD20 antibody, in the treatment of refractory pemphigus vulgaris". JAMA Dermatology. 150 (12): 1331–1335. doi:10.1001/jamadermatol.2014.1939. PMC 5897695. PMID 25133328.
Klufas DM, Amerson E, Twu O, Clark L, Shinkai K (August 2020). "Refractory pemphigus vulgaris successfully treated with ofatumumab". JAAD Case Reports. 6 (8): 734–736. doi:10.1016/j.jdcr.2020.05.034. PMC 7369462. PMID 32715065.
Werth VP, Joly P, Mimouni D, Maverakis E, Caux F, Lehane P, et al. (June 2021). "Rituximab versus Mycophenolate Mofetil in Patients with Pemphigus Vulgaris". The New England Journal of Medicine. 384 (24): 2295–2305. doi:10.1056/NEJMoa2028564. PMID 34097368. S2CID 235359759.
Daniel BS, Murrell DF (2014-05-06). "Management of pemphigus". F1000Prime Reports. 6: 32. doi:10.12703/P6-32. PMC 4017903. PMID 24860654.
Ellebrecht CT, Bhoj VG, Nace A, Choi EJ, Mao X, Cho MJ, et al. (July 2016). "Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease". Science. 353 (6295): 179–184. Bibcode:2016Sci...353..179E. doi:10.1126/science.aaf6756. PMC 5343513. PMID 27365313.

gene.com

"FDA Approves Genentech's Rituxan (Rituximab) for Pemphigus Vulgaris". Genentech. Retrieved 24 December 2019.

harvard.edu

ui.adsabs.harvard.edu

Ellebrecht CT, Bhoj VG, Nace A, Choi EJ, Mao X, Cho MJ, et al. (July 2016). "Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease". Science. 353 (6295): 179–184. Bibcode:2016Sci...353..179E. doi:10.1126/science.aaf6756. PMC 5343513. PMID 27365313.

nih.gov

pubmed.ncbi.nlm.nih.gov

Cholera M, Chainani-Wu N (June 2016). "Management of Pemphigus Vulgaris". Advances in Therapy. 33 (6): 910–958. doi:10.1007/s12325-016-0343-4. PMC 4920839. PMID 27287854.
King DF, Holubar K (October 1983). "History of pemphigus". Clinics in Dermatology. 1 (2): 6–12. doi:10.1016/0738-081X(83)90019-6. PMID 6400552.
Gupta VK, Kelbel TE, Nguyen D, Melonakos KC, Murrell DF, Xie Y, et al. (July 2011). "A globally available internet-based patient survey of pemphigus vulgaris: epidemiology and disease characteristics". Dermatologic Clinics. 29 (3): 393–404, vii–iii. doi:10.1016/j.det.2011.03.016. PMID 21605804.
Maity, Subhadeep; Banerjee, Ishita; Sinha, Rupam; Jha, Harshvardhan; Ghosh, Pritha; Mustafi, Subhasish (2020). "Nikolsky's sign: A pathognomic boon". Journal of Family Medicine and Primary Care. 9 (2): 526–530. doi:10.4103/jfmpc.jfmpc_889_19. ISSN 2249-4863. PMC 7114071. PMID 32318376.
Ahmed AR, Kaveri S, Spigelman Z (December 2015). "Long-Term Remissions in Recalcitrant Pemphigus Vulgaris". The New England Journal of Medicine. 373 (27): 2693–2694. doi:10.1056/NEJMc1508234. PMID 26716930.
de-la-Rosa-Fernández E, Loizate-Sarrionandia I, González-Rodríguez J, Herrero-Moyano M, Fernández-de-Misa-Cabrera R, Suárez-Hernández J (April 2023). "Ocrelizumab, an alternative to rituximab in refractory pemphigus vulgaris management". Journal of the European Academy of Dermatology and Venereology. 37 (9): e1104 – e1106. doi:10.1111/jdv.19133. PMID 37102356. S2CID 258355167.
Ellebrecht CT, Choi EJ, Allman DM, Tsai DE, Wegener WA, Goldenberg DM, Payne AS (December 2014). "Subcutaneous veltuzumab, a humanized anti-CD20 antibody, in the treatment of refractory pemphigus vulgaris". JAMA Dermatology. 150 (12): 1331–1335. doi:10.1001/jamadermatol.2014.1939. PMC 5897695. PMID 25133328.
Klufas DM, Amerson E, Twu O, Clark L, Shinkai K (August 2020). "Refractory pemphigus vulgaris successfully treated with ofatumumab". JAAD Case Reports. 6 (8): 734–736. doi:10.1016/j.jdcr.2020.05.034. PMC 7369462. PMID 32715065.
Werth VP, Joly P, Mimouni D, Maverakis E, Caux F, Lehane P, et al. (June 2021). "Rituximab versus Mycophenolate Mofetil in Patients with Pemphigus Vulgaris". The New England Journal of Medicine. 384 (24): 2295–2305. doi:10.1056/NEJMoa2028564. PMID 34097368. S2CID 235359759.
Daniel BS, Murrell DF (2014-05-06). "Management of pemphigus". F1000Prime Reports. 6: 32. doi:10.12703/P6-32. PMC 4017903. PMID 24860654.
Ellebrecht CT, Bhoj VG, Nace A, Choi EJ, Mao X, Cho MJ, et al. (July 2016). "Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease". Science. 353 (6295): 179–184. Bibcode:2016Sci...353..179E. doi:10.1126/science.aaf6756. PMC 5343513. PMID 27365313.

ncbi.nlm.nih.gov

Cholera M, Chainani-Wu N (June 2016). "Management of Pemphigus Vulgaris". Advances in Therapy. 33 (6): 910–958. doi:10.1007/s12325-016-0343-4. PMC 4920839. PMID 27287854.
Maity, Subhadeep; Banerjee, Ishita; Sinha, Rupam; Jha, Harshvardhan; Ghosh, Pritha; Mustafi, Subhasish (2020). "Nikolsky's sign: A pathognomic boon". Journal of Family Medicine and Primary Care. 9 (2): 526–530. doi:10.4103/jfmpc.jfmpc_889_19. ISSN 2249-4863. PMC 7114071. PMID 32318376.
Ellebrecht CT, Choi EJ, Allman DM, Tsai DE, Wegener WA, Goldenberg DM, Payne AS (December 2014). "Subcutaneous veltuzumab, a humanized anti-CD20 antibody, in the treatment of refractory pemphigus vulgaris". JAMA Dermatology. 150 (12): 1331–1335. doi:10.1001/jamadermatol.2014.1939. PMC 5897695. PMID 25133328.
Klufas DM, Amerson E, Twu O, Clark L, Shinkai K (August 2020). "Refractory pemphigus vulgaris successfully treated with ofatumumab". JAAD Case Reports. 6 (8): 734–736. doi:10.1016/j.jdcr.2020.05.034. PMC 7369462. PMID 32715065.
Daniel BS, Murrell DF (2014-05-06). "Management of pemphigus". F1000Prime Reports. 6: 32. doi:10.12703/P6-32. PMC 4017903. PMID 24860654.
Ellebrecht CT, Bhoj VG, Nace A, Choi EJ, Mao X, Cho MJ, et al. (July 2016). "Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease". Science. 353 (6295): 179–184. Bibcode:2016Sci...353..179E. doi:10.1126/science.aaf6756. PMC 5343513. PMID 27365313.

patient.info

"Pemphigus Vulgaris | Causes, Symptoms and Treatment". patient.info. 2 May 2018. Retrieved 2019-11-18.

pemphigus.org

"Pemphigus". www.pemphigus.org. Retrieved 2019-12-03.

rarediseases.org

"Pemphigus and Pemphigoid". NORD (National Organization for Rare Disorders). Retrieved 2019-11-18.

semanticscholar.org

api.semanticscholar.org

Beigi PK (2018). "History of Pemphigus Vulgaris". A Clinician's Guide to Pemphigus Vulgaris. Springer, Cham. p. 13. doi:10.1007/978-3-319-67759-0_3. ISBN 978-3-319-67758-3. S2CID 91065046.
de-la-Rosa-Fernández E, Loizate-Sarrionandia I, González-Rodríguez J, Herrero-Moyano M, Fernández-de-Misa-Cabrera R, Suárez-Hernández J (April 2023). "Ocrelizumab, an alternative to rituximab in refractory pemphigus vulgaris management". Journal of the European Academy of Dermatology and Venereology. 37 (9): e1104 – e1106. doi:10.1111/jdv.19133. PMID 37102356. S2CID 258355167.
Werth VP, Joly P, Mimouni D, Maverakis E, Caux F, Lehane P, et al. (June 2021). "Rituximab versus Mycophenolate Mofetil in Patients with Pemphigus Vulgaris". The New England Journal of Medicine. 384 (24): 2295–2305. doi:10.1056/NEJMoa2028564. PMID 34097368. S2CID 235359759.

timesofisrael.com

Shamah D (April 20, 2012). "Researchers Discover Gene Responsible for Devastating Skin Disease". The Times of Israel. Retrieved 30 December 2022.

uptodate.com

"Pathogenesis, clinical manifestations, and diagnosis of pemphigus". www.uptodate.com. Retrieved 2017-04-03.

web.archive.org

Kaplan DL (2009). "Dermclinic". Consultant. 49 (3). Archived from the original on 2012-02-13. Retrieved 2009-04-02.

worldcat.org

search.worldcat.org

Maity, Subhadeep; Banerjee, Ishita; Sinha, Rupam; Jha, Harshvardhan; Ghosh, Pritha; Mustafi, Subhasish (2020). "Nikolsky's sign: A pathognomic boon". Journal of Family Medicine and Primary Care. 9 (2): 526–530. doi:10.4103/jfmpc.jfmpc_889_19. ISSN 2249-4863. PMC 7114071. PMID 32318376.